Dive into the archives.
- Hot off the ECTRIMS Press…Alemtuzumab Shows Lasting Benefits in RRMS
(RTTNews) - Friday, biotechnology company Genzyme Corp. said that four-year follow-up data from its completed Phase [...]
- Hot off the ECTRIMS Press…Fewer Injection Site Reactions with Avonex
CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon (interferon beta-1b), Copaxone (glatiramer Acetate) or Rebif (interferon beta-1a). [...]
- Hot off the ENS Press…Rebif Autoinject Improves SC Delivery
MILAN, Italy
June 26, 2009
A new electronic, multidose, autoinjection device improves subcutaneous delivery of interferon beta (IFNB)-1a in patients with relapsing multiple sclerosis (MS), according to a study presented here at the 19th Meeting of the European Neurological Society (ENS2009).
Virginia Devonshire, MD, Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, presented [...]
